BCRX BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

• 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.
• 7th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.
• Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:John Bluth+1 919 859 7910jbluth@biocryst.com